RE:RE:RE:RE:RE:SP
cashascars wrote: In actual fact we only need 3 of the remaining 17 pending to hit CR at 450 days for us to beat both of the already approved Vicinium at 17% and Ketruda at 19%. If we get 7 out of 33 CR we would be coming in at 21%.
Its a given in my mind and its only a matter of time before we get the results( in that prove I'm right with my investing this time around. We will be way way off of this currant share price when this is approved in less time than we all think.
cashascars
Yep, not a lot of competition standing in our way...I believe Vicineum's BLA was actually denied by the FDA earlier this year. Outside of Keytruda, the only other drug that's been FDA approved for BCG-refractory NMIBC is an intravesical chemotherapeutic (Valrubicin), which has a measly 8% 2-year response rate.